These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3526 related articles for article (PubMed ID: 18957670)
1. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ; J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670 [TBL] [Abstract][Full Text] [Related]
2. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971 [TBL] [Abstract][Full Text] [Related]
3. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. Kristiansen M; Knudsen GP; Maguire P; Margolin S; Pedersen J; Lindblom A; Ørstavik KH J Med Genet; 2005 Nov; 42(11):877-80. PubMed ID: 15879497 [TBL] [Abstract][Full Text] [Related]
4. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414 [TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Dagan E; Friedman E; Paperna T; Carmi N; Gershoni-Baruch R Eur J Hum Genet; 2002 Nov; 10(11):724-8. PubMed ID: 12404104 [TBL] [Abstract][Full Text] [Related]
7. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392 [TBL] [Abstract][Full Text] [Related]
8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123 [TBL] [Abstract][Full Text] [Related]
10. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771 [TBL] [Abstract][Full Text] [Related]
11. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547 [TBL] [Abstract][Full Text] [Related]
12. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA; Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659 [TBL] [Abstract][Full Text] [Related]
14. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453 [TBL] [Abstract][Full Text] [Related]
15. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836 [TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751 [TBL] [Abstract][Full Text] [Related]
17. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399 [TBL] [Abstract][Full Text] [Related]
18. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881 [TBL] [Abstract][Full Text] [Related]
19. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Rafnar T; Benediktsdottir KR; Eldon BJ; Gestsson T; Saemundsson H; Olafsson K; Salvarsdottir A; Steingrimsson E; Thorlacius S Eur J Cancer; 2004 Dec; 40(18):2788-93. PubMed ID: 15571962 [TBL] [Abstract][Full Text] [Related]
20. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]